Winslow Evans & Crocker Inc. grew its holdings in Amgen, Inc. (NASDAQ:AMGN) by 2.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,256 shares of the medical research company’s stock after buying an additional 162 shares during the period. Winslow Evans & Crocker Inc.’s holdings in Amgen were worth $1,190,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also modified their holdings of AMGN. BKD Wealth Advisors LLC lifted its holdings in shares of Amgen by 3.9% in the fourth quarter. BKD Wealth Advisors LLC now owns 4,032 shares of the medical research company’s stock valued at $785,000 after purchasing an additional 150 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Amgen by 2.2% in the fourth quarter. Quadrant Capital Group LLC now owns 3,958 shares of the medical research company’s stock valued at $749,000 after purchasing an additional 85 shares in the last quarter. Advisors Capital Management LLC lifted its holdings in shares of Amgen by 65.1% in the fourth quarter. Advisors Capital Management LLC now owns 8,152 shares of the medical research company’s stock valued at $1,587,000 after purchasing an additional 3,214 shares in the last quarter. Appleton Partners Inc. MA lifted its holdings in shares of Amgen by 15.0% in the fourth quarter. Appleton Partners Inc. MA now owns 23,987 shares of the medical research company’s stock valued at $4,670,000 after purchasing an additional 3,127 shares in the last quarter. Finally, Joel Isaacson & Co. LLC lifted its holdings in shares of Amgen by 3.3% in the fourth quarter. Joel Isaacson & Co. LLC now owns 3,432 shares of the medical research company’s stock valued at $688,000 after purchasing an additional 111 shares in the last quarter. 78.01% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have recently commented on AMGN. Mizuho set a $208.00 price target on Amgen and gave the company a “buy” rating in a report on Friday, April 12th. Royal Bank of Canada restated a “neutral” rating and issued a $192.00 price target on shares of Amgen in a report on Tuesday. Citigroup upgraded Amgen from a “neutral” rating to a “buy” rating and cut their price target for the company from $211.00 to $205.00 in a report on Wednesday. Credit Suisse Group began coverage on Amgen in a report on Monday, May 20th. They issued an “outperform” rating and a $208.00 price target on the stock. Finally, BidaskClub lowered Amgen from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $209.05.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, April 30th. The medical research company reported $3.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The business had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.55 billion. During the same quarter in the prior year, the company posted $3.47 earnings per share. Amgen’s revenue was up .1% on a year-over-year basis. On average, research analysts forecast that Amgen, Inc. will post 13.94 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 3.39%. Amgen’s payout ratio is presently 40.28%.
In related news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $175.73, for a total transaction of $351,460.00. Following the sale, the director now owns 15,092 shares in the company, valued at $2,652,117.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 6,000 shares of company stock worth $1,115,580 in the last quarter. 0.25% of the stock is currently owned by corporate insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Recommended Story: Overbought
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.